Lv6
1887 积分 2024-05-13 加入
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma
23天前
已完结
Bruton tyrosine kinase inhibitors plus chemoimmunotherapy in previously untreated younger mantle cell lymphoma patients: Single-centre clinical outcomes
23天前
已完结
Optimizing Fixed‐Duration Ven‐I Regimen in CLL: Expert Insight and AI Comparison
24天前
已完结
Unsolved issues in CLL biology and management
1个月前
已完结
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
1个月前
已完结
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
1个月前
已完结
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
2个月前
已完结
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia
2个月前
已完结
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
2个月前
已完结
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
2个月前
已完结
皖公网安备34019202002308
